NASDAQ:AKCA - Nasdaq -
18.17
+0.03 (+0.17%)
The current stock price of AKCA is 18.17 null. In the past month the price increased by 0.17%. In the past year, price decreased by -8%.
Akcea Therapeutics, Inc. is a biopharmaceutical company. It focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The Company's drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx which are in clinical stage. Akcea Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Akcea Therapeutics Inc
22 BOSTON WHARF RD 9TH FLOOR
BOSTON MA 02210
CEO: Damien McDevitt
Phone: 617-207-0202
The current stock price of AKCA is 18.17 null. The price increased by 0.17% in the last trading session.
The exchange symbol of Akcea Therapeutics Inc is AKCA and it is listed on the Nasdaq exchange.
AKCA stock is listed on the Nasdaq exchange.
Akcea Therapeutics Inc (AKCA) has a market capitalization of 1.85B null. This makes AKCA a Small Cap stock.
Akcea Therapeutics Inc (AKCA) has a support level at 18.14 and a resistance level at 18.18. Check the full technical report for a detailed analysis of AKCA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AKCA does not pay a dividend.
Akcea Therapeutics Inc (AKCA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.54).
ChartMill assigns a technical rating of 8 / 10 to AKCA. When comparing the yearly performance of all stocks, AKCA is one of the better performing stocks in the market, outperforming 76.92% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to AKCA. AKCA has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months AKCA reported a non-GAAP Earnings per Share(EPS) of -0.54. The EPS increased by 65.82% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -12.34% | ||
ROA | -7.86% | ||
ROE | N/A | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 60% to AKCA. The Buy consensus is the average rating of analysts ratings from 3 analysts.